EClinCloud CTO Wu Weiping: A Runner on the Path of Technological Innovation

The following article is from
"
E
-Pharma Manager
" (E药经理人) WeChat official account
In Beijing in May, a faint floral scent filled the morning air. Dressed in athletic wear, Wu Weiping was running along the street with steady strides and even breathing.
He is a regular marathon runner and has also competed in
"100-kilometer trail races" that test extreme endurance-running standards. Running is Wu Weiping's attitude toward life; he not only runs on different tracks, but also keeps moving forward on the journey of IT technological innovation.
This year marks year
11 of Wu Weiping's consistent running and year 4 since joining EClinCloud.
EClinCloud is a startup focused on innovative digital solutions for clinical trials; Wu Weiping, company founder Qin Long, and Chief Commercial Officer Su Quanyu are work partners who have known each other for more than
10 years. Similar industry experience, a shared love of sports, and a common dream of transforming clinical research through technological innovation brought them together.
They deeply understand that innovative technology can drive progress in the healthcare industry:
"Technological innovation brings effective treatments to patients." EClinCloud is dedicated to serving the specialized fields of new drug R&D and device innovation. The products it develops must both meet regulatory requirements across countries worldwide and help pharmaceutical companies, innovative medical device companies, CROs, and study sites improve efficiency and accelerate the path to market for drugs or devices, helping patients receive better treatments faster. As Chief Technology Officer, Wu Weiping faces immense pressure and challenges.
▲ EClinCloud founding team (from left: Chief Commercial Officer Su Quanyu, Chief Executive Officer Qin Long, and Chief Technology Officer Wu Weiping)
01
"3 8-Year Periods": A Pioneer in Digital Solutions for Clinical Research in China
Before joining EClinCloud, Wu Weiping's career can be summarized simply as
3 8-year periods.
After graduating from Tsinghua University with a major in Computer Science and Technology, he joined
the Financial Services Division of IBM (China) Systems Co., Ltd., where he spent 8 years working on the research, development, and rollout of new systems. IBM was one of the global leaders in technological innovation at the time, and technological transformation in the financial industry was the most advanced across all sectors, placing Wu Weiping at the forefront of technological innovation from the start.
In 2005, Wu Weiping earned a master's degree in economics from Peking University and joined Oracle the same year, beginning the 2nd 8-year period of his career. At Oracle, he entered the life sciences field for the first time and, in 2011, became General Manager of Oracle's Life Sciences Business Unit for Greater China, forging a lasting connection with technological innovation in the life sciences.
Wu Weiping is a pioneer in promoting
clinical trial systems such as EDC and PV systems in China.
Having long been at the forefront of technological innovation, after entering the life sciences field, he keenly observed that in new drug R&D,
the application of new IT technologies lagged far behind that in the financial industry or internet sector, this field had an even greater need for the support of technological innovation, and digital technology would play a crucial role in this field.
"When working with scientists engaged in new drug R&D, you will find they are very different from IT clients in other fields," Wu Weiping said. Out of reverence for life, they care about every detail of the data process and take scientific rigor to the utmost level. Facing such a group of scientists and investigators, Wu Weiping is full of confidence in the life sciences field.

▲ Wu Weiping discussing the development of digital technology
He spent the
3rd eight-year period of his career at Hitachi Data Systems (China) Co., Ltd., where he served as Chief Technology Officer for China and managed a technical team of more than 150 people. During those eight years, he was not only a technical expert, but also an accomplished senior manager. Running forward through successive role upgrades, he felt the resilience of life and experienced the power of perseverance.
02
Joining EClinCloud: He Is the Company's Most
AI-Savvy "Anchor"
Deeply rooted
in the IT sector for nearly 30 years, serving in successive C-level leadership roles at multinational technology giants... Wu Weiping could have kept jogging on the track of international corporations, yet he chose to enter a more challenging but promising "cross-country race."
In 2020, at the invitation of founder Dr. Qin Long, he joined the startup EClinCloud as Chief Technology Officer, overseeing the company's technology roadmap and product R&D strategy.
Dr. Qin Long believed he could lead EClinCloud to realize its dream, not only because of his extensive experience in technological innovation, but even more so because of their shared values regarding the use of new technology to empower the life sciences
—through "technological innovation that brings effective treatments to patients."
"He is the veteran everyone at the company respects most, and the mainstay of EClinCloud," Dr. Qin Long remarked. Wang Xinjie, a project manager at EClinCloud's R&D Center, greatly admires Wu Weiping: "Mr. Wu is very decisive. He can make decisions and solve problems quickly—for example, in BI technology selection and architecture design, he combines business scenarios with the overall technical setup of the company's platform to select the most suitable solution."
Wu Weiping is tasked with strategic responsibilities including building the technical team, selecting platform technologies, and planning the product R&D roadmap.
He and his team are driven by customer needs, bringing products closer to real customer needs while uncovering the deeper intent behind those needs. Given the complexity and diversity of clinical trials, Wu Weiping established EClinCloud's
"no-code" and "Lego-style" component-and-configuration technical approach, which can flexibly address customers' various complex needs. Along the way, he has emphasized "empowering every step with brand-new technologies" to achieve platform-wide intelligence and empower every role involved in clinical research.
Wu Weiping recognized early on the immense potential of AI technology. Even before ChatGPT came out, he had noticed that AI technology would bring major changes to the industry, spending at least 2 hours every evening learning about and studying AI technology. In the eyes of his colleagues, "He is the person in the entire company who is best at working with AI. Mr. Wu's long-standing habit of running has kept his youthful energy and agile thinking; he consistently reads international literature, leads us in consistently taking MOOCs, and regularly shares the most advanced technologies."
What makes IT unique is that you cannot rest on past achievements; the development of new technologies will bring sweeping changes. At Wu Weiping's suggestion, EClinCloud's R&D Center set up an Innovation Center in early 2023 dedicated to exploring the application of AI in clinical research. In his view, everything from data to documents, and from recognition and database build to data mining and analysis across the entire clinical study, can be connected through automation, and AI will make the entire workflow smarter. He disclosed that in the second half of 2024, "more AI technologies will be applied to EClinCloud's platform, greatly improving the platform's intelligence."
03
Two Clouds in China and the US: Architects and Practitioners of EClinCloud's Internationalization Strategy
Wu Weiping and the rest of the company's core management team all have extensive management experience at multinational companies, and they likewise possess a global outlook and forward-looking mindset,
which led EClinCloud to establish an international development strategy from its founding.
Starting with the company's first product, the R&D team led by Wu Weiping took international standards as its starting point—not only developing systems with multilingual support, but also ensuring that the technology can meet the regulatory requirements of different countries and regions such as China, the United States, and the European Union. They pay particular attention to data privacy protection and compliance, stressing that in clinical
trials,
protecting trial participants' privacy is a primary consideration.
To achieve this goal,
Wu Weiping decided to adopt a dual-cloud technical architecture spanning China and the United States.
This architecture allows the platform to automatically determine where data is stored based on project requirements, thereby ensuring data security and compliance. Through this flexible technical approach, EClinCloud adapts better to the needs of different markets and assists clients in implementing their internationalization strategies. Over the past
4 years, EClinCloud has not only developed multiple clinical trial systems, including eCOA, CTMS, eTMF, EDC, RTSM, and RM, but has also provided services such as scale management and rater training. These systems and services are all deployed on the dual-cloud platform and have supported multiple multinational, multicenter research projects.
▲Wu Weiping presenting product value at the 2023 EClinCloud User Conference
EClinCloud's goal goes beyond achieving domestic substitution for clinical trial systems; more importantly, it is to support the global expansion strategies of innovative Chinese pharmaceutical companies and become their digital solutions partner for international projects. Wu Weiping said:
"In the past, we helped foreign-invested companies implement technology in China; today, we help our clients go global with independently developed products. Being able to apply our past experience to advancing the internationalization of Chinese pharmaceutical companies makes me very proud."
Wu Weiping meets technological innovation in a runner's stride, combining cutting-edge technology with the life sciences to empower new drug R&D through digitalization and intelligent technologies.
At the end of April, Wu Weiping ran in the Beijing Daxing Half Marathon again; before the race, he deliberately pinned on an EClinCloud badge and set off into the woods and fields of flowers with the guiding principle of "bringing effective treatments to patients through technological innovation."

▲ Wu Weiping competing in various running events


